Thanks to a preliminary in vitro screening of several CCl 3 -substituted-nitrogen containing heterocycles belonging to our chemical library, the 2-trichloromethylquinoxaline scaffold appeared to be of potential interest for developing new antiplasmodial agents. Then, combining these experimental results to the antimalarial properties reported for variouspyrrolo[1,2-a]quinoxaline derivatives, an original series of fifteen 7-substituted-4-trichoromethylpyrrolo[1,2-a]quinoxalines was synthesized in a 4 to 5 reaction steps pathway.
Introduction
Nowadays, malaria still remains one of the most prevailing and lethal infectious disease worldwide. The protozoa parasite responsible for this infection belongs to the Plasmodiumgenus and is transmitted to humans by the bite of the infectedAnopheles mosquito female. Among the fivePlasmodium species responsible for malaria, the most lethal is P. falciparum, causing cerebral malaria. According to the WHO, in 2012, malaria affected about 207 million people in the inter-tropical area and caused an estimated 627,000 deaths [1] .
Artemisinin-based combination therapies (ACTs) are recommended by the WHO as the firstline treatment for treating malaria caused by P. falciparum. Unfortunately, parasite resistance to artemisinin derivatives has now been detected in 4 countries of the Greater Mekong subregion: Cambodia, Myanmar, Thailand and Vietnam [2] [3] [4] [5] [6] . This emerging resistance of P. falciparum strains is a serious problem for the containment and the treatment of this disease as it could lead to a resurgence of more virulent levels of malaria, unless new chemical entities,displaying novel mechanisms of action, be rapidly found [7] [8] [9] [10] .
Aiming at synthesizing original molecules displaying antiparasitic properties [11] [12] [13] [14] [15] , our research group previously reported promising results in 4-substituted-2-trichloromethylquinazoline series, showing that the trichloromethyl group was crucial for the in vitro activity against Plasmodium falciparum [16] [17] [18] [19] [20] . These results prompted us to investigate wider the anti-infectious potential of various aromatic nitrogen-containing heterocyclic scaffolds bearing a trichloromethyl group, in a view to identify new antiplasmodial candidates.
Results and discussion

Preliminary antiplasmodial screening of various trichloromethylated heterocyclic scaffolds
An antiplasmodial screening was first made from a series of closely related compounds corresponding to aromatic 6-membered bicyclic nitrogen-containing heterocycles bearing a Molecules 1a, 2a, 4a and 5a were prepared from their corresponding methylated precursors (1b, 2b and 5b, purchased from Sigma-Aldrich) by a microwave-assisted chlorination reaction using PCl 5 and POCl 3 [21, 22] . Molecule 4b was prepared as described by Liu and co-workers by reacting acetamidine hydrochloride with 2-bromobenzylamine in the presence of CuBr as catalyst [23] .Compound 3awas obtained by using an alternative route which was previously developed in our lab [24, 25] . Thus, 4-chloroquinazoline was reacted with bromotrichloromethane in the presence of tetrakis(dimethylamino)ethylene (TDAE) instead of using hazardous chlorine gas, as described in the literature [26] . Then, all these molecules were tested in vitro and compared with two commercial reference-drugs: chloroquine and doxycycline. For all tested compounds, the corresponding selectivity indexes (SI) were calculated. The results are presented in Table 1 .
<Insert Table 1 .> Among all tested compounds, only the quinoline, isoquinoline or quinoxaline derivatives bearing a CCl 3 group showed some potential in vitro antiplasmodial activity (respectively compounds 1a, 2a and 5a), in comparison with chloroquine or doxycycline. The quinazoline derivatives including a CCl 3 group at position 2 or 4 (compounds 4a and 3a) did not display significant activity. These last results indicated that the CCl 3 group was not sufficient alone for providing antiplasmodial activity in quinazoline series and suggested that the position of the CCl 3 group on the quinazoline ring could also play a key-role toward biological activity.
Moreover, when comparing the activities of the CCl 3 containing compounds to their CH 3 analogs, in all tested series, it clearly appeared that the CCl 3 group was involved in the antiplasmodial activity, in accordance with the experimental results which we previously obtained in 4-substituted quinazoline series [16] [17] [18] [19] .
Although displaying antiplasmodial activity, quinoline 1a and isoquinoline 2a did not appear to be the most potent compounds because of their rather high IC 50 values (respectively 8.5 and 8 M), in comparison with quinoxaline 5a (IC 50 = 1.5 M)and reference-drugs chloroquine (IC 50 = 0.6 µM) and doxycycline (IC 50 = 6.0 µM). Nevertheless, 5a showed a significant in vitro cytotoxicity (CC 50 = 3.1 M) in comparison with doxorubicine (CC 50 = 0.2 µM), making this compound poorly selective and unsuitable for further development. In order to validate the SARs of 5a, in addition to its methylated precursor 5b, three closely related analogs (5c, 5d and 5e) were also tested (Figure 2) . Compound 5c was prepared by a chlorination reaction of 5b using PCl 5 and POCl 3 ,under milder conditions than those used to prepare 5a, while compounds 5d and 5e were purchased from Aldrich.
<Insert Figure 2.>
The comparison of the results noted for the tested quinoxaline derivatives 5a-e indicated that the quinoxaline ring, itself, did not show any antiplasmodial potential (IC 50 of 5e> 50 M) and that the CCl 3 group was the only one that could confer antiplasmodial potential to the studied series, when located at position 2 of the quinoxaline ring (Table 1) .
Then, trying to reach a new 2-trichloromethylquinoxaline derivative presenting an improved antiplasmodial profile, we synthesized compound 5f in a view to compare its biological profile to the one of its antiplasmodial quinazoline position isomer which we previously reported [16] (Figure 3) . 5f was prepared from its corresponding methylated precursor which was synthesized according to the literature [27] by a microwave-assisted chlorination reaction using PCl 5 and POCl 3 .
<Insert Figure 3 .> Indeed, quinoxaline 5f appeared to be much more selective than 5a(SI = 17.5 versus 2.1, respectively), presenting a quite low antiplasmodial IC 50 value (0.2 M), better than the one of its quinazoline position isomer (IC 50 = 8 M). However, quinoxaline 5f remained too cytotoxic (CC 50 = 3.5 M) for allowing further investigations.
Such interesting result noted with compound 5f prompted us to carry on the investigation of the antiplasmodial potential of the 2-trichloromethylquinoxaline scaffold, especially when water/methanol 95/5; 6 < t < 7 min, linear decrease in the proportion of water to return to a ratio 50/50 water/methanol; 6 < t < 7 min, water/methanol 50/50. The water used was buffered with 5 mM ammonium acetate. The retention times (t R ) of the molecules analyzed are indicated in min. The preparation of compounds1a [21, 35] , 3a [24, 26] , 4b [22] , 5a [21] , 11a [37, 38] and 12a [33] was achieved as described in the literature. Compounds 1b, 2b, 5b, 5d and 5e were purchased from Sigma-Aldrich.
1-(Trichloromethyl)isoquinoline (2a)
A 100-mL round-bottomed flask equipped with a drying tube-condenser and a magnetic stir bar was charged with 1-methylisoquinoline (500 mg, 3.49 mmol), 
2-(Trichloromethyl)quinazoline (4a)
A 100-mL round-bottomed flask equipped with a drying tube-condenser and a magnetic stir 
2-(Dichloromethyl)quinoxaline (5c)
A 100-mL round-bottomed flask equipped with a drying tube-condenser and a magnetic stir bar was charged with 2-methylquinoxaline (2.0 g, 13.87 mmol), POCl 3 (2.59 mL, 27.74 mmol) and PCl 5 (5.78 g, 27.74 mmol). The mixture was refluxed for 12 h. After the reaction mixture was cooled with an ice bath, the mixture was carefully poured into 200 mL of ice.
The mixture was made alkaline by addition of NaHCO 3 . 
2-Phenyl-3-(trichloromethyl)quinoxaline (5f)
A 50-mL round-bottomed flask equipped with a drying tube-condenser and a magnetic stir bar was charged with 2-methyl-3-phenylquinoxaline [27] Hz, 2H, H-2'), 6.34 (t, J = 2.0 Hz, 2H, H-3'), 3.75 (sl, NH 2 ). 
Representative procedure for the preparation of 2,2,2-trichloro-N-[5-substituted-2-(1H-pyrrol-1-yl)phenyl]acetamide (9a-i)
A 100-mL round-bottomed flask equipped with a condenser, an Ar inlet and a magnetic stir bar was charged with appropriated 5-substituted-2-(1H-pyrrol-1-yl)aniline (15.0 mmol), 25 mL of anhydrous dioxane, triethylamine (3.14 mL, 22. 
N-[2-(1H-Pyrrol-1-yl)phenyl]-2,2,2-trichloroacetamide (9a)
Yield 65%. Off-white powder. Mp 79°C. 1 
Representative procedure for the preparation of 7-substituted-4-(trichloromethyl)pyrrolo[1,2-a]quinoxaline (10a-i)
A 100-mL round-bottomed flask equipped with a condenser, an Ar inlet and a magnetic stir 
In vitroCytotoxicity evaluation
HepG2 cell line was maintained at 37 °C, 6% CO 2 , 14% O 2 , 80% N 2 , with 90% humidity in RPMI supplemented with 10% foetal bovine serum, 1% L-glutamine (200 mM) and penicillin (100 U/mL) / streptomycin (100 µg/mL) (complete RPMI medium). The evaluation of the tested molecules cytotoxicity on the HepG2 (hepatocarcinoma cell line purchased from ATCC, ref HB-8065) cell line was performed according to the method of Mosmann [40] with slight modifications. Briefly, 5.10 3 cells in 100 µL of complete medium were inoculated into each well of 96-well plates and incubated at 37 °C in a humidified 6% CO 2 . After 24 h incubation, 100 μL of medium with various product concentrations dissolved in DMSO (final concentration less than 0.5% v/v) were added and the plates were incubated for 72 h at 37 °C.
Triplicate assays were performed for each sample. Each plate-well was then microscopeexamined for detecting possible precipitate formation before the medium was aspirated from the wells. 100 μL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) solution (0.5 mg/mL in medium without FCS) were then added to each well. Cells were incubated for 2 h at 37 °C. After this time, the MTT solution was removed and DMSO (100 μL) was added to dissolve the resulting blue formazan crystals. Plates were shaken vigorously (700 rpm) for 10 min. The absorbance was measured at 570 nm with 630 nm as reference wavelength using a BIO-TEK ELx808 Absorbance Microplate Reader. DMSO was 
